Thus, we reasonably hypothesize that in CRC, SLNT most likely inhibits the downstream AKT signaling axis by impeding the interaction between CD133 protein and p85, thereby exerting its anti-cancer effect. The gene discussed is PROM1; the disease is colorectal carcinoma.